Study of the safety and efficacy of the drug Angipur in acute coronary syndrome with ST-segment elevation (STEMI) and high-risk percutaneous transluminal coronary angioplasty(CTCAP) in comparison with eptifibatide.Material and methods. The study involved 157 patients with STEMI. High-risk CTCAP included massive or total coronary artery thrombosis, no-reflow/slow-reflow phenomenon, acute stent thrombosis. 55 people received Angipur at 0,72 mg/kg, 52 – 0,40 mg/kg, 50 – Integrilin. Clinical and laboratory studies, electrocardiography (ECG), and coronary angiography were carried out.

According to the criteria "Frequency and severity of hemorrhagic complications, including hemorrhagic stroke", and "Frequency, severity, seriousness of other adverse events" the safety of Angipur at doses of 0.40 and 0.72 mg/kg and Integrilin did not differ. Complaints, clinical symptoms, vital signs, general and biochemical blood tests, coagulograms, ECG in patients of different groups were similar and had unidirectional dynamics. Angipur or Integrilin was considered effective if no adverse outcomes of the disease (death, repeated acute ischemic event, the need for urgent re-revascularization) were observed for 30 days. There were no fatalities. One repeated acute ischemic event was registered in each group. In the groups of patients who received Angipur at a dose of 0.40 mg/ kg and received Integrilin, urgent re-revascularization was required once. 

Angipur and Integrilin have similar safety and efficacy.

Angipur, eptifibatide, coronary angioplasty.